AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06764056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Participants receiving this intervention will be seeing a registered dietician at each visit. The individualized approach will be based on recent literature (mostly hypocaloric) by using different methods.
Study NCT06763614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dog assisted therapy - animal interventions
Description: Animal Assisted Therapy is when animals are used in goal directed treatment sessions. These goals are working emotionalaspects pf childres and adolescents with SAF
Study NCT06764095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine and blood sample collection
Study NCT06764095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT06764095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Undergo cytoreductive cystectomy
Study NCT06764095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given IV
Study NCT06764095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Therapy
Description: Undergo MDT
Study NCT06764095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06764095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT06764095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06764095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06764095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ureterectomy
Description: Undergo ureterectomy
Study NCT06762938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: Apply ShotBlocker
Study NCT06763302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blinatumomab
Description: The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
Study NCT06763302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
Study NCT06763562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-first meal
Description: Rice eaten first (150 grams), followed by edamame (150 grams) and butter (10 grams)
Study NCT06763562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-last meal
Description: Edamame (150 grams) and butter (10 grams) eaten first, followed by rice (150 grams)
Study NCT06763965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioTTT001 injection
Description: BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.
Study NCT06764420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine Oral Suspension
Description: Participants in this group will receive an oral suspension containing 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. This control intervention serves to compare the effects of glutamine alone with the combined arginine and glutamine treatment. In addition to the glutamine suspension, patients in this group will receive general measures and analgesic drugs according to the WHO scale to manage symptoms of mucositis.
Study NCT06764420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine and Glutamine Oral Suspension
Description: Participants in this group will receive an oral suspension containing 5 grams of arginine and 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. The swish and swallow technique involves patients swishing the solution around the oral mucosa to ensure even distribution before swallowing. This intervention aims to evaluate the combined effect of arginine and glutamine on reducing the severity of radiation-induced mucositis, improving mucosal healing, and providing symptomatic relief.
Study NCT06763601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSMP, Isometric exercise, eccentric exercise, heavy slow resistance , functional program
Description: In this group the patients will be given symptom modification procedure in the first phase followed by isometric exercises in second phase, eccentrics and HSR in third phase and functional program in fourth phase
Study NCT06763601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MWM,Isometric exercise, eccentric exercise, heavy slow resistance , functional program
Description: in this mobilization with movement in first phase will be given followed by isometrics, eccentrics and heavy slow resistance exercise and finally the functional program
Study NCT06763601 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham mobilization
Description: Sham mobilization followed by isometrics, eccentric training and heavy resistance training and finally the functional program .
Study NCT06764537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection (40 mL) in glioblastoma patients
Study NCT06764290 — intervention group
Intervention type: OTHER
Intervention: pedal walking
Description: Pedal walking is a challenging walking task that can be used as a form of physical therapy for stroke participants.
Study NCT06764290 — intervention group
Intervention type: OTHER
Intervention: visual occlusion
Description: Walking with eyes-covered is a challenging walking task that can be used as a form of physical therapy for stroke participants.
Study NCT06763666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine
Description: Given IV
Study NCT06763666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT06763666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study NCT06763666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT06763666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Given SC
Study NCT06763666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given SC
Study NCT06763666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06763354 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection
Description: On the examination bed, the patient was placed in the lying truncated position, the perineum was disinfected with a towel, and a double-lumen urinary catheter was inserted via the perineum.Inject 50ml saline to clean the bladder once, open the drainage bag to drain.1mci SGC8 was dissolved in 50ml physiological saline. The drainage bag was clamped shut and 50ml of developer was injected into the bladder through the catheter, followed by 10ml of gas or saline (all developer in the ureter was injected into the bladder. The catheter was closed for 1 hour, during which time the patient was placed in the flat position, left lateral position, right lateral position, and supine position changing positions every 15 minutes.After 1 hour, the drainage bag was opened, the bladder was emptied with radioactive fluid, and the urine bag was replaced.
Study NCT06764173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oat drink
Description: 6 dl of oat drink daily
Study NCT06764173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oat drink
Description: 6 dl of oat drink daily
Study NCT06764173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk
Description: 6 dl of cow's milk daily
Study NCT06764173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow's milk
Description: 6 dl of cow's milk daily
Study NCT06764199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy (ACT), a relatively new psychotherapy, incorporates psychopathological hypotheses and interventions based on contextual behavioral sciences and Relational Frame Theory.
Study NCT05655026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV, HFNO
Description: Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.
Study NCT05654792 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter aortic valve implantation
Description: Transcatheter aortic valve implantation in cases of severe aortic stenosis
Study NCT03540355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipros 20 association
Description: oral, once a day
Study NCT03540355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 20 mg
Description: Oral, once a day
Study NCT06140901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Study morphological and functional of respiratory epithelium
Description: The working's investigators hypothesis is that the morphology and functional of the epithelium of children with ADV or RV respiratory infection is different between those who progress to PIBO and those who do not.
Study NCT05716152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Morning blood sample and skin punch biopsy of 4 mm diameter.
Description: 1. Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~2. Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody
Study NCT04297436 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 4CMenB (Bexsero®) vaccine
Description: Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030. The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.
Study NCT05600998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
Study NCT05600049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (815-v1 001) to (815-v1 050)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study).~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT05600049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype (815-v1 051) to (815-v1 100)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT05600049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (815-v1 101) to (815-v1 150)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT05600049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (815-v1 151) to (815-v1 200)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study NCT06013943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab+Gemox
Description: All of drugs were used for 6-8 cycles at the combined treatment stage, then Envafolimab and Gemcitabine continued at maintenance treatment stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 1 years.~Combined treatment stage: Envafolimab(150mg, iH, Q1W, Day1)+Gemcitabine(1000mg/m2, iv, Q3W, Day1 and Day8)+Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8);~Caintenance treatment stage: Envafolimab(400mg, iH, Day1, Q3W)+Gemcitabine(1000mg/m2, po, Day1-14, Q3W).
Study NCT05199363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information leaflet
Description: Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?
Study NCT05199363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational movie
Description: Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?
Study NCT05199363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demonstration
Description: Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers
Study NCT05005585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant
Description: immediate implant placement with VST technique versus early implant placement with contour augmentation technique
Study NCT06347484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-informed Recruitment Method of Contact
Description: The intervention being studied here is the method of contact (patient portal vs. email vs. postal mail) after being identified in the EHR
Study NCT06347484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Text-Messages and Connection to Cardiovascular Research Opportunities
Description: All participants who enroll in CONNECT, regardless of method of contact, will receive educational text messages and connection to cardiovascular research opportunities. Text messages will be tailored and include content on cardiovascular health promotion and research participation.
Study NCT06346821 — intervention group
Intervention type: DEVICE
Intervention: Optune® (Tumor Treating Fields)
Description: TTFields at 200 kHz to the brain using the Optune® System
Study NCT05166538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: direct-acting oral P2Y12-receptor antagonist
Study NCT05166538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: platelet aggregation inhibitor
Study NCT05898984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI
Description: CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[200 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg.~Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg.~Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
Study NCT05898984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI
Description: with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg
Study NCT05898984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)
Description: pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
Study NCT04884360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets 300 mg oral twice daily
Study NCT04884360 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo tablets taken orally at a dose of 300 mg twice daily
Study NCT06294366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Bowa device
Description: Bipolar Bowa device used in prostatic resection and enucleation
Study NCT06388616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balcinrenone
Description: 50 mg, Immediate release capsule to be taken orally.
Study NCT04237103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral capsules taken once a week
Study NCT04237103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administered identically to the experimental group
Study NCT04769323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
Study NCT04845919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid
Description: SDT treatment with 5-ALA using the ExAblate Model 4000 Type-2 Neuro-System.
Study NCT04769323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional home exercises
Description: Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
Study NCT05966402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Immersion in Virtual Reality
Study NCT04305691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT04305691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04305691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05139602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous Injection